May 28, 2026 – 8.00pmSuperannuation giant HESTA is the major investor in a new venture capital firm, which has banked close to $60 million for its debut fund, that will target investments in early stage Australian health and medical technology start-ups.Synthesis Capital is targeting a total of $70 million for its first fund and has taken two years to reach this stage, after also raising funds from family offices, global health industry executives and the Menzies Leadership Foundation.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber? Fetching latest articles